Cargando…
Morbilliform Eruption After Administration of Second Dose of Oxford/AstraZeneca Vaccine
Morbilliform eruption typically implies a maculopapular rash of acute onset. Drugs are the predominant cause of this cutaneous reaction in adults, followed by infectious exanthems and some rheumatological diseases. In this article, we report on the clinical and histopathological features of generali...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9156371/ https://www.ncbi.nlm.nih.gov/pubmed/35663693 http://dx.doi.org/10.7759/cureus.24649 |
_version_ | 1784718437954617344 |
---|---|
author | Alhammad, Norah S Milibary, Heba H Baghdadi, Razan R Alawadi, Toleen M Hudairy, Rawan E |
author_facet | Alhammad, Norah S Milibary, Heba H Baghdadi, Razan R Alawadi, Toleen M Hudairy, Rawan E |
author_sort | Alhammad, Norah S |
collection | PubMed |
description | Morbilliform eruption typically implies a maculopapular rash of acute onset. Drugs are the predominant cause of this cutaneous reaction in adults, followed by infectious exanthems and some rheumatological diseases. In this article, we report on the clinical and histopathological features of generalized pruritic morbilliform eruption in a 28-year-old female following her second dose of Oxford/AstraZeneca COVID-19 vaccine. The reaction started 12 hours after receiving the vaccine with no other identifiable cause. The patient had no improvement with IV antihistamine received in the emergency department. Afterward, she showed marked improvement after receiving a short course of oral corticosteroids along with topical corticosteroid and oral antihistamine. To the best of our knowledge, we hypothesize that the basic immunological mechanism is the cause behind COVID-19-vaccine-related morbilliform eruption. Therefore, physicians should be aware of the possible adverse reactions associated with COVID-19 vaccines, such as morbilliform eruptions and other cutaneous manifestations. |
format | Online Article Text |
id | pubmed-9156371 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-91563712022-06-02 Morbilliform Eruption After Administration of Second Dose of Oxford/AstraZeneca Vaccine Alhammad, Norah S Milibary, Heba H Baghdadi, Razan R Alawadi, Toleen M Hudairy, Rawan E Cureus Dermatology Morbilliform eruption typically implies a maculopapular rash of acute onset. Drugs are the predominant cause of this cutaneous reaction in adults, followed by infectious exanthems and some rheumatological diseases. In this article, we report on the clinical and histopathological features of generalized pruritic morbilliform eruption in a 28-year-old female following her second dose of Oxford/AstraZeneca COVID-19 vaccine. The reaction started 12 hours after receiving the vaccine with no other identifiable cause. The patient had no improvement with IV antihistamine received in the emergency department. Afterward, she showed marked improvement after receiving a short course of oral corticosteroids along with topical corticosteroid and oral antihistamine. To the best of our knowledge, we hypothesize that the basic immunological mechanism is the cause behind COVID-19-vaccine-related morbilliform eruption. Therefore, physicians should be aware of the possible adverse reactions associated with COVID-19 vaccines, such as morbilliform eruptions and other cutaneous manifestations. Cureus 2022-05-01 /pmc/articles/PMC9156371/ /pubmed/35663693 http://dx.doi.org/10.7759/cureus.24649 Text en Copyright © 2022, Alhammad et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Dermatology Alhammad, Norah S Milibary, Heba H Baghdadi, Razan R Alawadi, Toleen M Hudairy, Rawan E Morbilliform Eruption After Administration of Second Dose of Oxford/AstraZeneca Vaccine |
title | Morbilliform Eruption After Administration of Second Dose of Oxford/AstraZeneca Vaccine |
title_full | Morbilliform Eruption After Administration of Second Dose of Oxford/AstraZeneca Vaccine |
title_fullStr | Morbilliform Eruption After Administration of Second Dose of Oxford/AstraZeneca Vaccine |
title_full_unstemmed | Morbilliform Eruption After Administration of Second Dose of Oxford/AstraZeneca Vaccine |
title_short | Morbilliform Eruption After Administration of Second Dose of Oxford/AstraZeneca Vaccine |
title_sort | morbilliform eruption after administration of second dose of oxford/astrazeneca vaccine |
topic | Dermatology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9156371/ https://www.ncbi.nlm.nih.gov/pubmed/35663693 http://dx.doi.org/10.7759/cureus.24649 |
work_keys_str_mv | AT alhammadnorahs morbilliformeruptionafteradministrationofseconddoseofoxfordastrazenecavaccine AT milibaryhebah morbilliformeruptionafteradministrationofseconddoseofoxfordastrazenecavaccine AT baghdadirazanr morbilliformeruptionafteradministrationofseconddoseofoxfordastrazenecavaccine AT alawaditoleenm morbilliformeruptionafteradministrationofseconddoseofoxfordastrazenecavaccine AT hudairyrawane morbilliformeruptionafteradministrationofseconddoseofoxfordastrazenecavaccine |